A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether deferoxamine (DFO) given
intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal
metastasis from solid tumor cancer. The researchers will test different doses of DFO to find
the highest dose that causes few or mild side effects. When the dose is found, they will test
it in future participants to see whether DFO is a safe and effective treatment for people
with leptomeningeal metastasis from non-small cell lung cancer (NSCLC). They are also doing
this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Center for Experimental Therapeutics F.M. KIRBY FOUNDATION